A TWIN-SHIME system was used to compare the metabolism of pomegranate polyphenols by the gut microbiota from two individuals with different urolithin metabotypes. Gut microbiota, ellagitannin metabolism, short-chain fatty acids (SCFA), transport of metabolites, and phase II metabolism using Caco-2 cells were explored. The simulation reproduced the in vivo metabolic profiles for each metabotype. The study shows for the first time that microbial composition, metabolism of ellagitannins, and SCFA differ between metabotypes and along the large intestine. The assay also showed that pomegranate phenolics preserved intestinal cell integrity. Pomegranate polyphenols enhanced urolithin and propionate production, as well as Akkermansia and Gordonibacter prevalence with the highest effect in the descending colon. The system provides an insight into the mechanisms of pomegranate polyphenol gut microbiota metabolism and absorption through intestinal cells. The results obtained by the combined SHIME/Caco-2 cell system are consistent with previous human and animal studies and show that although urolithin metabolites are present along the gastrointestinal tract due to enterohepatic circulation, they are predominantly produced in the distal colon region.
■ INTRODUCTION
Dietary ellagitannins (ETs) and ellagic acid (EA) have been associated with important health effects and benefits in diseases including cardiovascular disease. 1, 2 They are present in dietary sources in larger amounts than previously estimated. 3 In humans, ETs are not absorbed as such, and the absorption of EA is rather low. 4 Both ETs and EA are catabolized by the gut microbiota leading to urolithin metabolites. 5 The final metabolites in this catabolic conversion are urolithin A (Uro-A), urolithin B (Uro-B), and isourolithin A (Isouro-A) ( Figure  1 ). Not all individuals have the appropriate gut microbiota to produce the final urolithin metabolites, and three different urolithin metabotypes (UMs), UM-A, UM-B, and UM-0, have been reported. 6 Species of the genus Gordonibacter have been identified as gut microbiota constituents that are involved in the conversion of EA into intermediary urolithins. 7, 8 Fecal Gordonibacter concentrations correlate positively with urolithin-A content in feces and urine, 9 although other unknown bacterial species are needed to produce the final urolithin metabolites. Urolithins reach concentrations within the micromolar range in human plasma, 10, 11 and these bioavailable metabolites trigger different molecular and cell responses that may account, at least partially, for the antioxidant, antiinflammatory, anticancer, cardio-metabolic, and neuroprotective effects attributed to ETs and (or) to ET-containing foods. 2, 5, 12, 13 Therefore, the study of the mechanisms for urolithin production, the identification of the specific regions of the intestine where they are formed, and the gut microbiota involved are of special interest. After pomegranate polyphenols intake, several urolithins have been detected in human feces, urine, and also in biopsies taken from prostate and different regions of the colon in cancer patients. 14, 15 In vitro production of urolithins from EA by human fecal microbiota from both metabotypes A and B has also been described. 16 However, the gastrointestinal tract site for urolithin production, the stability, and absorption of the metabolites in the gut are still unknown. To date, Gordonibacter levels have only been quantified in human fecal samples, but its distribution throughout the digestive tract and its role in urolithin production are still unknown. Fecal Gordonibacter levels are higher in urolithin metabotype A (UM-A) individuals than in those with urolithin metabotype B (UM-B) and urolithin metabotype 0 (UM-0). 17 Modulation of some human fecal bacteria by consumption of ET-rich food such as pomegranate has recently been described, 18, 19 and the increase of fecal Gordonibacter levels was highlighted. 19 However, modulation of Gordonibacter and other bacterial groups by ET-rich foods along the digestive tract as well as their differences between metabotypes has not been explored and requires further research.
In the present study, a simulator of the human intestinal microbial ecosystem (TWIN-SHIME) was used to shed light on ET gut microbiota metabolism in the different regions of the intestine. A pomegranate extract (PE) supplement was subjected to a stomach and small intestine (SI) digestion to estimate the bioavailability of native polyphenols and their catabolism in the upper part of the gastrointestinal tract. Longterm microbial colon fermentation was also investigated in the TWIN-SHIME, thus determining the gut microbiota metabolism of ETs in the colon, the urolithin production pathway, the sites of transformation, and the metabolite profile of (poly)phenolics which have potential to be absorbed. The production of specific SCFA was also evaluated, as well as the modulation of gut microbiota. The intestinal transport and cell metabolism of the (poly)phenolics were also evaluated through direct addition of diluted phenolics-containing SHIME matrix to Caco-2-cells. Overall, our results are of interest to validate this system when compared with the results previously obtained in vivo. 
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Article ■ MATERIALS AND METHODS Pomegranate Extract (PE) and Chemicals. Characterized PE was provided by Laboratorios Admira S.L. (Alcantarilla, Murcia, Spain). 19 EA, punicalagin and 6,7-dihydroxycoumarin (DHC) were from Sigma-Aldrich (St. Louis, MO, USA). Urolithins were obtained as previously described. 3 Purity was higher than 95% for all tested compounds. Organic solvents such as methanol, acetone, and acetonitrile were from Merck (Darmstadt, Germany). All chemicals and reagents were of analytical grade.
Volunteer Stratification and Characterization. To select the fecal donors for UM-A and UM-B, 13 individuals consumed 30 g walnuts/day for 3 days, and urine samples were collected on the third day. Urolithin production and metabolic profiles were evaluated using HPLC-DAD-MS, 20 and eight individuals were stratified as UM-A, four as UM-B, and one as UM-0. This distribution is consistent with normal values as previously reported. 20,6 Representatives of UM-A and UM-B were selected as fecal donors for the assay of ET metabolism in the gastrointestinal simulator.
Metabolism of the ETs in the TWIN-SHIME and Sampling. A SHIME setup (registered name from Ghent University and ProDigest), simulating the entire human gastrointestinal tract, was used as previously reported. 21−23 To investigate two different metabotypes (UM-A and UM-B) at the same time, a TWIN-SHIME setup 23 was used by operating two systems in parallel. The first two reactors are of the fill-and-draw principle to simulate different steps in food uptake and digestion, with peristaltic pumps adding a defined amount of SHIME nutritional medium (140 mL 3×/day) and pancreatic and bile liquid (60 mL 3×/day), respectively, to the stomach and small intestine (SI) compartments and emptying the respective reactors after specified intervals. The last three compartments simulate the ascending (AC), transverse (TC), and descending (DC) colon. Inoculum preparation, retention time, pH, temperature settings, and reactor feed composition were previously described. 23 After inoculating the colon reactors of the TWIN-SHIME system with fresh fecal samples from UM-A and UM-B, a two-week stabilization period allowed the microbial community to differentiate in the reactors. After the stabilization period, the standard SHIME nutrient matrix was further dosed to the model for 2 weeks. Analysis of samples in this control period allowed us to determine the baseline microbial community composition and activity in the different reactors, which were used as a control to compare with the results from the treatment period where the basic diet was supplemented with 1.8 g/day of PE during 3 weeks. TWIN-SHIME samples obtained from the different reactors (SI, AC, TC, and DC) were analyzed. Samples were taken for chemical (ET derived metabolites and SCFA profile) and microbial (denaturing gradient gel electrophoresis (DGGE) and quantitative PCR (qPCR)) analyses.
EA and Urolithin LC-MS Analysis. Samples (2 mL) from the different vessels of the TWIN-SHIME were extracted with 2 mL of ethyl acetate acidified with 1.5% formic acid. The mixture was vortexed for 2 min and centrifuged at 3500g for 10 min. The organic phase was separated and evaporated under reduced pressure to dryness. The dry samples were then redissolved in 400 μL of methanol and filtered through a 0.22 μm PVDF filter. Then, 5 μL of 10 μg/mL of internal standard (6,7-dihydroxycoumarin) was added to 50 μL of the sample before the injection onto a column for HPLC-DAD-single Q analysis. Several samples were also analyzed after 1:10 dilution in methanol to quantify compounds present at very high concentrations (saturated compounds). Samples (0.5 mL) from the Caco-2 transport experiment were extracted with 0.5 mL of acetonitrile/formic acid (2%). After vortexing the samples for 2 min, they were centrifuged for 15 min at 14,000g. The supernatants were collected, dried using nitrogen, and stored at −80°C until HPLC-MS analyses. Samples were analyzed as described previously, 3, 20 using HPLC-DAD-MS with a reversed-phase column. All metabolites were quantified with their standards at 305 nm, except for EA, punicalagin, and Uro-M7 at 360 nm. These were quantified with an EA calibration curve at 360 nm. The method validation previously reported 3,20 was adapted regarding recovery and the limits of detection and quantification using this matrix (SHIME medium) (Suppl. Table 1) .
SCFA Analysis. TWIN-SHIME samples were analyzed as previously described. 24 Briefly, SCFA were extracted from the samples with diethyl ether, after the addition of 2-methyl hexanoic acid as an internal standard. Extracts were analyzed using a GC-2014 gas chromatograph (Shimadzu, Hertogenbosch, The Netherlands), equipped with a capillary fatty acid-free EC-1000 Econo-Cap column (dimensions, 25 mm × 0.53 mm; film thickness, 1.2 mM; Alltech, Laarne, Belgium), a flame ionization detector, and a split injector. The injection volume was 1 mL, and the temperature profile was set from 110 to 160°C, with a temperature increase of 6°C/min. The carrier gas was nitrogen, and the temperature of the injector and detector was 100 and 220°C, respectively.
DNA Extraction and Microbial Analysis. Powerfecal DNA isolation kit (Mo-Bio Laboratories, Carlsbad, CA, USA) was used to isolate total DNA from different SHIME samples. An additional step was done consisting of vigorous shaking using a FastPrep Instrument and 2 mL tubes containing special beads (MP Biomedicals, LLC, Ohio, USA). After DNA extraction, DGGE was used to monitor the most prominent shifts within the overall microbial community together with group-specific shifts within the total bacteria 25 and Clostridium cluster XIVa. 26 After DNA extraction and PCR with general or group-specific primers, DGGE was performed to separate PCR products. 25, 26 Gels had a denaturizing gradient from 45% to 60% and were run using a DCodeTM Universal Mutation Detection System (Bio-Rad). Data analysis was carried out using GelCompar version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium). Pearson correlation and UPGMA (Unweighted Pair Group Method using Arithmetic Mean) clustering were used to calculate dendrograms of DGGE profiles.
qPCR for total bacteria, Firmicutes, Bacteroidetes, Bacteroides spp., Bif idobacterium spp., Lactobacillus spp., Akkermansia spp., and Gordonibacter spp., was performed as previously reported. 17, 19 Realtime qPCR was run on the ABI 7500 system (Applied Biosystems, ABI, Madrid, Spain) following the manufacturer's conditions.
Maintenance of Intestinal Cell Culture. The human colon adenocarcinoma cell line Caco-2 (HTB37) was obtained and cultured as reported previously. 27 Cells were maintained in an incubator with a water saturated atmosphere of 10% CO 2 at 37°C (Memmert CO 2 incubator, Memmert GmbH & Co., Nurnberg, Germany). The cell culture medium was replaced 3 times a week, and when Caco-2 cells reached 80−90% confluence, the cells were subcultured using 0.25% (v/v) trypsin-EDTA solution (Sigma-Aldrich).
Cytotoxicity Measurements. Using MTT and SRB assays, the cytotoxicity of (i) PE-free intestinal matrix, (ii) digested PE, and (iii) undigested PE on the intestinal Caco-2 cells was investigated. 27, 28 Intestinal Caco-2 cells were maintained for 21 days to obtain confluent monolayers of differentiated intestinal cells as previously reported. 27, 28 21 Days postseeding, the Caco-2 monolayers were loaded for 4 h with 1/5 (v/v) dilutions of the intestinal matrix and the (un)digested PE in HBSS. 29 Subsequently, the MTT and SRB assays were performed to monitor mitochondrial activity and protein content, respectively. 27, 28 Intestinal Transport. Caco-2 cells were seeded on the apical side of the Transwell filters of 6-well Transwell plates (0.4 μm pore diameter, 24 mm insert, Corning Costar Co., Elscolab, Kruibeke, Belgium), and after 21 days, a 100% confluent monolayer was obtained. Intestinal monolayer integrity measurements were performed as previously reported. 27, 28 To ensure that the intestinal Caco-2 cell monolayer (i) is intact during the transport assays and (ii) is not permanently damaged by the treatment, the transepithelial electrical resistance (TEER) of the monolayer was measured before, immediately after, and 24 h after the transport assays. The paracellular transport was also assessed 24 h after the transport assays using the fluorescent paracellular transport marker Lucifer Yellow. On the basis of in-house experience, 27, 28 Hank's balanced salt solution (HBSS) (Gibco Life Technologies) was selected as a transport medium. Cells were washed and preincubated with the transport medium (HBSS) for 1 h. Next, cells were treated with dilutions of (i) PE-free intestinal matrix, (ii) digested PE, and (iii) undigested PE dissolved in HBSS (2
Article mL, pH 6.5), while fresh HBSS (2.5 mL, pH 7.5) was loaded in the basal compartment and incubated for 4 h (37°C and 10% CO 2 ). Samples (0.5 mL) from the apical and basal compartments were obtained after 2 and 4 h of treatment.
Statistical Analysis. All samples were analyzed in triplicate. All data are expressed as the mean value ± SD. Statistical analyses were performed using SPSS V.23 for Windows (SPSS, Chicago, IL, USA). Two-way ANOVA was performed to evaluate differences between groups. Bonferroni posthoc test was used to investigate differences between stages. Statistical significance was accepted at P < 0.05. To study differences between the different stages of the experiment, twoway ANOVA with Bonferroni test was applied to the data. For the cytotoxicity measurements, the treatments were compared using oneway ANOVA followed by a Tukey posthoc test with significance levels of p < 0.05, p < 0.01, and p < 0.001.
■ RESULTS

Identification of ETs and Gut Microbiota Metabolites.
Characteristic HPLC chromatograms of the two metabotypes are shown in Figure 2 . The main analytical parameters of urolithin metabolites in the SHIME medium and the LOD and LOQ (Suppl. Table 1 ) are similar to those previously reported. 20 The polyphenol constituents of the PE and the hydrolysis products were detected in very small quantities ( Figure 2 ). EA, however, was the main metabolite observed in all of the gut compartments (data not shown). The PE metabolites produced in the different SHIMEcompartments (SI, AC, TC, and DC) were analyzed ( Figure 3 ). The analysis of the SI samples showed a profile in which only small amounts of PE ETs and hydrolysis products were detected, while no urolithins were produced apart from trace amounts of urolithin M5 (Uro-M5). In contrast, the metabolic profile in large intestine compartments differed qualitatively and quantitatively between metabotypes. UM-B produced Isouro-A and Uro-B, while these metabolites were not detected in the samples from UM-A (Figures 1 and 3 ). Uro-A and intermediate metabolites such as the urolithin M5, M6, D, E, C, and M7 were detected in the large intestine compartments from both metabotypes (Figures 1, 2 , and 3), although in some cases at very low concentrations. Differences in metabolic kinetics were observed along large intestine compartments for both metabotypes. Urolithin concentration before and after PE administration showed an increase in urolithin production. In fact, only in the DC, Uro-A was produced from the start of PE administration for both metabotypes (Figure 3 ). In the AC, urolithin-A was detected in UM-B during the third week of PE treatment but not in UM-A samples. In TC, Uro-A was produced during the second week of PE treatment in the case of UM-B, while almost no urolithins were observed in UM-A even after 3 weeks of PE treatment (Figure 3 ). In UM-B, Isouro-A production also started during the first, second, and third week of PE administration in the case of DC, TC, and AC, respectively. In DC, Uro-B appeared during the second week of PE treatment, in parallel with the Isouro-A decrease and the Uro-A increase. After 18 days, the main urolithin detected in DC was Uro-A for both metabotypes (100% in UM-A and 88% in UM-B).
Production of SCFA. Concentrations of acetate, propionate, butyrate, and total SCFA were higher in the distal than proximal intestine ( Figure 4 ). Differences between metabotypes were also observed. Initially, butyrate production was higher in UM-B than in UM-A in the case of AC and TC. These differences were maintained after 3 weeks of PE administration and also observed in DC. Changes in SCFA production were already observed after 1 week. In AC, there was a reduction of total SCFA and butyrate for both metabotypes. Total SCFA and butyrate levels were, however, similar to initial levels after 3 weeks of treatment ( Figure 4 ). An increase in propionate was detected in TC from UM-A but also in DC from both metabotypes. A decrease in acetate was observed but only in UM-A.
Gut Microbiota Composition. UM-A and UM-B clustered differently in the dendrogram obtained for total bacteria (Suppl. Figure 1 ). Moreover, for each metabotype, the AC profiles differed from their respective TC and DC profiles that were more similar between them. PE treatment induced a shift in microbial composition for both metabotypes, while the initial difference between proximal (AC) and distal colon regions (TC and DC) became less pronounced. DGGE was also performed for Clostridium cluster XIVa. While no clear differences between both metabotypes could be observed (Suppl. Figure 1) , the community profiles of the AC were again different from those of the TC and DC. Further, in contrast with the total bacterial profiles, it followed that the two main clusters consisted of the 
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Article control versus the treatment samples, revealing a more pronounced PE effect on the Clostridium cluster XIVa. This distinct PE effect also resulted in reduced differences between proximal (AC) and distal compartments (TC and DC). Different microbial groups (total bacteria, Firmicutes, Bacteroidetes, as well as Bacteroides, Bifidobacteria, Akkermansia, lactic acid bacteria, and Gordonibacter spp.) were monitored by qPCR analysis (Table 1) . Before PE administration, higher levels of Akkermansia and Gordonibacter were observed in the distal colon (TC and DC) than in the proximal colon (AC) of both metabotypes. In contrast, levels of Firmicutes, Bacteroidetes, as well as Bacteroides and Bifidobacteria were higher in AC than in DC. The comparison of microbiota changes before and after the 3 weeks of PE administration demonstrated a significant (P < 0.05) enhanced growth of total bacteria in both metabotypes in TC (Table 1) . A total bacteria increase was also observed in DC but only in UM-A. PE induced changes mainly in the DC and especially in UM-A. Thus, Bacteroidetes, Bacteroides, Akkermansia, lactic acid bacteria and Gordonibacter increased immediately after starting the PE treatment while Bif idobacte- 
Article rium decreased. In UM-B, some significant changes were also observed in DC but only in lactic acid bacteria and Gordonibacter which increased (Table 1 ). In AC, modulation of different microbial groups was also more evident in UM-A than in UM-B, particularly in the case of Akkermansia, lactic acid bacteria, and Gordonibacter. However, Gordonibacter increase was much higher in DC than in AC (Table 1) . A positive correlation between Gordonibacter and Uro-A production was observed in DC (P = 0.007; r = 0.599) while such a correlation was not observed for Akkermansia (Table 2) . However, both Gordonibacter and Akkermansia were positively correlated between them (P = 0.018; r = 0.549) and also with propionate production. In contrast, these bacteria were not correlated with total SCFA (Table 2) or with acetate or butyrate (data not shown).
Cytotoxicity Measurements. Before transport assays, the cytotoxicity of the intestinal matrix and the (un)digested PE, as measured by the MTT and SRB assays, were investigated. MTT values did not significantly change when Caco-2 cells were treated with undigested PE. MTT values, however, significantly increased when Caco-2 cells were exposed to 1/5 dilutions of the PE-containing SI digest of both metabotypes compared to those of the untreated cells. The same trend was observed for 1/5 dilutions of the PE-containing AC digest of both metabotypes. For the other compartments, decreased MTT values were observed when the intestinal cells were exposed to 1/5 dilutions of the PE-free digests, especially for metabotype B, whereas the PE-containing digests caused an increased mitochondrial activity compared to that of the untreated cells ( Figure 5A ).
For SRB, the intestinal cells treated with the PE-free DC matrix of both metabotypes had a significant decrease in protein content. Interestingly, this possible toxic effect was prevented by the presence of PE for both metabotypes, in a 
Article similar way to the restoration of the mitochondrial activity under these conditions ( Figure 5B) .
Monolayer Integrity Measurement. After 1 h of preincubation with HBSS, the TEER values were overall well preserved (90 ± 12% − 112 ± 19% of initial values). After 4 h of incubation with intestinal matrix and (un)digested PE (immediately after the transport assays), a maximal decrease of 42% in the monolayer integrity was observed (data not shown). One day after the assays, the TEER values were partially restored to initial values, with an average recovery of 77%. Interestingly, the TEER values recovered to a higher extent when the Caco-2 cells were treated with PE-containing digests (maximal decrease of 36%) compared to PE-free digests (maximal decrease of 53%) ( Figure 6A ).
For all intestinal monolayers treated with PE digests of metabotype A, the P app values of apical-to-basolateral direction direction ranged from 2.66 ± 0.12 × 10 −6 cm/s to 5.78 ± 0.094 × 10 −6 cm/s, thereby still confirming a good quality of the monolayer. 28 The apparent permeability coefficient values of monolayers treated with PE-containing digests of metabotype A were significantly higher than the P app values of monolayers treated with PE-free digests.
Intestinal monolayers treated with the PE digest of metabotype B, especially of the TC and DC compartments, had higher apparent permeability coefficient values compared to those of metabotype A ( Figure 6B ). This increase in paracellular transport should be taken into account while interpreting the results of the transport assays. The apparent permeability coefficient values of intestinal monolayers loaded with PE digests of the TC and DC compartment of metabotype B were significantly higher than the P app values of monolayers treated with PE-free digests of these compartments.
Transport Assays. Caco-2 cells produced phase II conjugates, such as Uro-A-sulfate, when the monolayers were treated with PE-containing UM-A digests from the TC and DC, and Uro-A-sulfate, Isouro-A-sulfate, Uro-A-glucuronide, and Uro-B-sulfate in the case of UM-B (Suppl . Table 2A and B) . Table 3 shows the basal recoveries of various constituents when Caco-2 cells were exposed to (un)digested PE extract from a *, **, and ***: significant increase or decrease at P < 0.05, P < 0.01, and P < 0.001, respectively, from the beginning of treatment. 
Article UM-A and UM-B. Both punicalagin and EA were transported across the intestinal monolayer for all conditions, except when the Caco-2 cell monolayers were exposed to the descending colon digest of UM-A for 2. EA hexoside and EA pentoside transport were also observed when the intestinal monolayer was treated with the SI digest of both UMs. The transport assays also demonstrated for the first time that Uro-A was transported across the Caco-2 monolayer, as well as Isouro-A and Uro-B. Moreover, the intestinal cells produced (Iso)-Uro-A phase II metabolites (Uro-A-sulfate, Isouro-A-sulfate and Uro-A-glucuronide) that were transported to the basal side ( Figure  7 ).
■ DISCUSSION
The purpose of the study was to compare the intestinal metabolism of ETs and EA from PE in different regions of the human gastrointestinal tract. Production and distribution of urolithins along the intestine were previously investigated in vivo in Iberian pigs fed with an ET-rich diet, 30 but it is unknown in humans. For this purpose, fecal samples from two individuals, with distinct UMs, were introduced in the in vitro TWIN-SHIME system. The pathway of urolithin formation and the place in the intestinal tract where they are produced were elucidated. For both UMs, the highest urolithin production was carried out in DC. These results are consistent with those obtained in pigs where Uro-A and Uro-B were mainly produced at the distal parts of the intestine 30 and with the conclusions obtained from human intervention studies, in which urolithin started to appear in plasma and was excreted in urine at significant concentrations, around 24 h after EA intake. 4, 31 Therefore, TWIN-SHIME was suitable to reproduce the UMs observed in humans consuming PE. 19 Figure 3 shows that there is a clear difference between the gut microbiota metabolisms of UM-A and UM-B. These are differences in the type of metabolites produced, the place where they are formed, and the kinetics of their production. The results of the present study show that the production of final urolithin metabolites started earlier in UM-B and that its response to PE administration was faster than that of UM-A. Final urolithins were also produced in the AC in the case of UM-B, while they were not observed in UM-A before TC. These differences between UMs indicate that the gut microbiota present in UM-B can start the synthesis of Uro-A and Isouro-A in the AC, while the microbiota in UM-A are not able to produce urolithins under the ecological and physiological conditions of the AC and are very active under the conditions of the DC. In the same line, a study of the production of urolithins after the intake of ETs in cattle showed 
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Article that Isouro-A was mainly produced in the ruminal compartment, while Uro-A was mainly produced in the distal intestine. 32 Interestingly, urolithins and other pomegranatederived metabolites were previously detected and quantified in malignant and normal colonic tissues from different colon regions (AC, TC, and DC) in colorectal cancer patients that consumed PE for around 15 days. 15 In this study, the location of urolithins in the colonic tissues was independent of both the colon region and metabotype of the patients. These results do not agree with the specific detection of Uro-A in DC from the UM-A individual. However, this could be explained by the existence of an active enterohepatic circulation of urolithins as previously observed in the pig, whose bile was reported to be very rich in urolithin derivatives which can re-enter the small intestine. 30 This throws a new hypothesis by which urolithins should occur from the duodenum to the rectum of individuals upon chronic PE consumption.
A three-week addition of PE enhanced urolithin production in the TWIN-SHIME for both UMs. This was consistent with a recent trial in which overweight-obese subjects consumed the same PE and dose (1.8 g/d). 19 In the present study, PE enhanced, especially, Uro-A production in both UMs. Indeed, after 18 days of PE administration, the UM-B profile was quite similar to that of UM-A as the main urolithin was Uro-A (100% in UM-A and 88% in UM-B). In UM-B, it seems that Isouro-A is produced earlier, then decreases at the same time that Uro-B and Uro-A increase (Figure 3) , supporting previous observations in human intervention studies that suggested that Uro-B is much better produced from Isouro-A than from Uro-A. 16 As recently shown in humans, 14 this study confirms that intermediate metabolites such as urolithins M5, M6, D, E, C, and M7, are produced by both UMs, showing that the bacterial strains responsible for the UM-B only affect the removal of the hydroxyl at C-8 position, as this removal is needed for the production of Isouro-A and Uro-B. Both Uro-E and Uro-M7 that were only recently reported to be produced by the human gut microbiota 16 were present in significant amounts in both UMs, confirming that they are relevant intermediates in EA catabolism. In the present study, we showed that urolithins and ET precursors are transported across the Caco-2 cell monolayer, which metabolized Uro-A into both Uro-A sulfate and glucuronide as well as Isouro-A into Isouro-A sulfate, confirming previous results. 33 Sulfated and glucuronidated 
Article urolithins were also transported back across the Caco-2 cell monolayer which is also consistent with in vivo results. 19 Upon treatment of these communities with the PE, an initial decrease in SCFA production was observed in the AC, both in UM-A and UM-B. This reduction was absent in the TC and DC ( Figure 5 ). This observation could be explained by an initial toxic effect of the PE on the microbial communities which would only be observed in the AC since this is the region that received the highest dose of the product. By the time that it reached the TC and DC, the extract had already been diluted, and therefore, the effect was likely attenuated. After the first week of treatment, the bacterial groups in the AC probably adapted to the presence of the PE, and consequently, the initial activity and abundances were re-established. Changes in the proportions of SCFA were observed throughout the PE treatment consisting of a propionate increase for both UMs in DC. Low levels of butyrate and propionate bacterial producers have been associated with some diseases in which inflammation is involved. 34 According to this, the results obtained in this experiment indicate that the PE had a positive effect on gut health. Other SCFA changes by PE treatment were metabotype-dependent. In general, higher changes occurred in UM-A than in UM-B. For UM-A, acetate levels decreased after dosing the PE extract.
According to differences in urolithin and SCFA production along the intestinal tract, DGGEs (total and Clostridium cluster XIVa) and qPCR showed differences in bacterial composition along the large intestine, between UMs, and modulation of gut 
Article microbiota by PE administration. This microbial difference between proximal (AC) and distal (TC and DC) colon regions is consistent with previous observations. 23 Interestingly, the in vitro colon compartments derived from the two UMs contained a different gut microbiota as previously shown in vivo. 19 These differences might be related to the interindividual variation in gut microbiome metabolic activity between both donors (socalled urolithin metabotypes; UMs). Further, the treatment with the PE caused a strong long-term effect (treatment weeks 2 and 3) on the composition and the activity of the microbial communities, especially in UM-A as previously observed in humans. 19 For UM-A, there was an increase in Akkermansia and Bacteroides (together with the corresponding phylum Bacteroidetes). As these microbial groups are potent propionate producers, this nicely correlates with the shift from acetate to propionate for this donor in DC. The correlation of propionate with Gordonibacter is also interesting as PE treatment modulated this bacterial group. Regarding UM-B, there is a specific increase of Bacteroidetes in the DC which matches with the specific increase of propionate in that compartment. The relative abundance of Bacteroidetes has also been linked to the total fecal propionate concentration. 35 The capacity of Gordonibacter to transform EA into different urolithins has been reported. 8 To date, Gordonibacter has only been quantified in human fecal samples, and its distribution throughout the digestive tract and its role in the formation of certain urolithins are still unknown. This study confirms that Gordonibacter abundance is increased in both UMs along the intestine after PE administration. Furthermore, a direct relationship between Gordonibacter and urolithin-A production along the digestive track was observed as shown previously in vivo. 9 In the present study, we also observed an increase in Bacteroidetes and especially Akkermansia, in UM-A after 21 days of PE administration. This increase confirms results obtained in other in vitro studies that evaluated the effect of PE on human gut microbiota from different donors. 4, 36 The effect of pomegranate polyphenols on Akkermansia in human intervention trials with pomegranate juice of PE has not led to concluding results and deserves more study. 19, 37, 38 This positive bacterial modulation could contribute to the beneficial health effects of pomegranate as they are inversely correlated with body weight and type-2 diabetes. 39 Studies on the Caco-2 monolayer integrity showed that the presence of PE significantly empowered barrier function which is stressed with colon microbial environment. In all cases, the permeability coefficients of the monolayers treated with PE-free digest were higher compared to P app values of Caco-2 cells loaded with PE-containing digests, thereby showing that the presence of the PE counteracted the possible toxic effects of the intestinal matrix for both metabotypes. This protective effect was in line with the observed higher TEER recoveries for the monolayers treated with PE digests compared to monolayers loaded with PE-free digests. These results agree with previous observations showing that consumption of a PE-enriched diet caused an improvement in the intestinal mucosa barrier function of rats with dextran sodium sulfate (DSS)-induced inflammation 12 or obstructive jaundice. 40 This protective effect could be either due to a direct effect of the PE polyphenols on the intestinal cells, or to a change in the microbial community and metabolism caused by the presence of the PE. Epithelial barrier dysfunction is associated with inflammation and an increased TNF-α production, 41 and it has been observed that PE has anti-inflammatory activities and can reduce TNF-α levels in rats with chronic colitis. 42 In some studies, PE also stimulated the growth of Bifidobacterium spp. and Lactobacillus spp., 12, 36 which are known to enhance the intestinal epithelial barrier function. 43 In this study, however, bifidobacteria were not positively affected by PE.
The in vitro intestinal transport of punicalagin and EA is in agreement with previous studies that reported free EA in human plasma upon consumption of PE, 4 although intact punicalagin was not detected in the human plasma samples. However, the observed in vitro basolateral transport of punicalagin is consistent with a study showing the presence of punicalagin in the blood of rats fed a diet complemented with a high amount of punicalagin-rich pomegranate husk for one month. 44 In general, the results obtained are consistent with the previous observations in animal models and humans, 18, 19, 32, 37 and, therefore, support the combined TWIN-SHIME/Caco-2 cell system as a model to evaluate the gut microbiota metabolism of pomegranate ETs in the GI tract and described preliminary differences between UMs. Differences in microbial composition along the intestine and between UMs determine urolithin profiles. The present study has some limitations as only two donors from UM-A and UM-B were compared. However, this study contributes to elucidate the distribution of urolithins along the digestive tract, the mechanism involved in their production, the specific intestinal transport of urolithins and their phase-II conjugates, and the effects on the composition of gut microbiota under the ecological and physiological conditions at different sections of the colon.
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